- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1, 2,3, EMBRACE, for potential U.S. FDA New Drug Application in 2028 1,2,3 - - Phase 3 APPROACH pivotal study of HLP003 in
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce that it
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce the
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Amir Inamdar, Helus Pharma’s Chief Medical
Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP)
Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today welcomed the White House Executive Order aimed at accelerating
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus
Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical